Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

Resectability redefined: Lessons from quadruple therapy in HCC.

Nan Jiang1, Bin-Yan Zhong2

  • 1Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Med (New York, N.Y.)
|June 12, 2026
PubMed
Summary

A phase II trial shows promising results for combining sintilimab, lenvatinib, and TACE-HAIC as conversion therapy for unresectable hepatocellular carcinoma (uHCC). This approach offers a potential new strategy for treating advanced liver cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis.

European radiology experimental·2026
Same author

Precision transarterial chemoembolization in hepatocellular carcinoma: patient selection, standardized techniques, and quantitative evaluation.

Hepatobiliary surgery and nutrition·2026
Same author

Dysregulated lipid metabolism in hepatocellular carcinoma: a review of molecular networks and therapeutic opportunities.

Journal of advanced research·2026
Same author

Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study.

Liver cancer·2026
Same author

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma.

Alimentary pharmacology & therapeutics·2026

Area of Science:

  • Hepatobiliary cancers
  • Gastroenterology
  • Medical oncology

Background:

  • Unresectable hepatocellular carcinoma (uHCC) presents significant treatment challenges.
  • Conversion therapy aims to downstage uHCC for potential curative treatments.
  • Optimizing the combination of locoregional and systemic therapies is crucial for uHCC management.

Purpose of the Study:

  • To evaluate the efficacy of sintilimab, lenvatinib, and transarterial chemoembolization combined with hepatic arterial infusion chemotherapy (TACE-HAIC) as conversion therapy for uHCC.
  • To assess the potential of this combination regimen in improving outcomes for patients with uHCC.

Main Methods:

  • Phase II clinical trial (PLATIC).
  • Combination therapy including sintilimab (systemic immunotherapy), lenvatinib (tyrosine kinase inhibitor), and TACE-HAIC (locoregional therapy).

Related Experiment Videos

Last Updated: Jun 14, 2026

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

  • Evaluation of conversion therapy for unresectable hepatocellular carcinoma.

    • Main Results:

    • The combination therapy demonstrated substantial advances in conversion therapy for uHCC.
    • Results suggest potential for improved outcomes in patients with unresectable liver cancer.

    Conclusions:

    • The combination of sintilimab, lenvatinib, and TACE-HAIC shows promise as a conversion therapy for uHCC.
    • Further research is needed to determine the optimal integration of locoregional and systemic therapies in HCC treatment.